Across TCGA pan-cancer cohorts, IMPG2 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated IMPG2 data layer compared with 22 for mass-spec protein and 6 for mutation status.
The strongest signal is observed in glioblastoma multiforme (GBM), where higher IMPG2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated IMPG2 expression acts as an unfavorable survival marker.
GBM are the cancer types where IMPG2 mass-spec protein most reproducibly stratifies survival.